EasySep™ Human B Cell Enrichment Kit II Without CD43 Depletion

Immunomagnetic negative selection kit

More Views

From: 730 USD

Options

* Required Fields

Catalog # (Select a product)
Immunomagnetic negative selection kit
From: 730 USD

New look, same high quality and support! You may notice that your instrument or reagent packaging looks slightly different from images displayed on the website, or from previous orders. We are updating our look but rest assured, the products themselves and how you should use them have not changed. Learn more

Required Products

Overview

The EasySep™ Human B Cell Enrichment Kit II without CD43 Depletion is designed to isolate B cells by negative selection from fresh or previously frozen PBMCs of individuals with B cell leukemia or lymphoma, or other disease states in which B cells may express CD43. The EasySep™ procedure involves labeling unwanted cells with antibody complexes and magnetic particles. The magnetically labeled cells are separated from the untouched desired cells by using an EasySep™ magnet and simply pouring or pipetting the desired cells into a new tube.

This kit replaces the EasySep™ Human B Cell Enrichment Kit without CD43 (Catalog #19154) for even faster cell isolations.
Advantages:
• Fast and easy-to-use
• Up to 99% purity
• Isolated cells are untouched
Components:
  • EasySep™ Human B Cell Enrichment Kit II without CD43 Depletion (Catalog #17963)
    • EasySep™ Human B Cell Enrichment Cocktail II without CD43 Depletion, 1 mL
    • EasySep™ Isolation Cocktail Enhancer, 1 mL
    • EasySep™ Dextran RapidSpheres™, 1 mL
  • RoboSep™ Human B Cell Enrichment Kit II without CD43 Depletion (Catalog #17963RF)
    • EasySep™ Human B Cell Enrichment Cocktail II without CD43 Depletion, 1 mL
    • EasySep™ Isolation Cocktail Enhancer, 1 mL
    • EasySep™ Dextran RapidSpheres™, 1 mL
    • RoboSep™ Buffer (Catalog #20104)
    • RoboSep™ Filter Tips (Catalog #20125)
Magnet Compatibility:
• EasySep™ Magnet (Catalog #18000)
• “The Big Easy” EasySep™ Magnet (Catalog #18001)
• EasyEights™ EasySep™ Magnet (Catalog #18103)
• RoboSep™-S (Catalog #21000)
Subtype:
Cell Isolation Kits
Cell Type:
B Cells
Species:
Human
Sample Source:
PBMC
Selection Method:
Negative
Application:
Cell Isolation
Brand:
EasySep; RoboSep
Area of Interest:
Immunology

Scientific Resources

Educational Materials

(7)

Product Applications

This product is designed for use in the following research area(s) as part of the highlighted workflow stage(s). Explore these workflows to learn more about the other products we offer to support each research area.

Data and Publications

Data

Starting with fresh PBMCs, the B cell content (CD19+) of the enriched fraction is typically 84.9 ± 13.9% (mean ± SD using the purple EasySep™ Magnet). In the above example, the purities of the start and final enriched fractions are 14.8% and 85.8%, respectively.

Publications

(1)
The Journal of experimental medicine 2020 sep

Autologous tumor cell vaccine induces antitumor T cell immune responses in patients with mantle cell lymphoma: A phase I/II trial.

M. J. Frank et al.

Abstract

Here, we report on the results of a phase I/II trial (NCT00490529) for patients with mantle cell lymphoma who, having achieved remission after immunochemotherapy, were vaccinated with irradiated, CpG-activated tumor cells. Subsequently, vaccine-primed lymphocytes were collected and reinfused after a standard autologous stem cell transplantation (ASCT). The primary endpoint was detection of minimal residual disease (MRD) within 1 yr after ASCT at the previously validated threshold of ≥1 malignant cell per 10,000 leukocyte equivalents. Of 45 evaluable patients, 40 (89{\%}) were found to be MRD negative, and the MRD-positive patients experienced early subsequent relapse. The vaccination induced antitumor CD8 T cell immune responses in 40{\%} of patients, and these were associated with favorable clinical outcomes. Patients with high tumor PD-L1 expression after in vitro exposure to CpG had inferior outcomes. Vaccination with CpG-stimulated autologous tumor cells followed by the adoptive transfer of vaccine-primed lymphocytes after ASCT is feasible and safe.
PRODUCTS ARE FOR RESEARCH USE ONLY AND NOT INTENDED FOR HUMAN OR ANIMAL DIAGNOSTIC OR THERAPEUTIC USES UNLESS OTHERWISE STATED. FOR ADDITIONAL INFORMATION ON QUALITY AT STEMCELL, REFER TO WWW.STEMCELL.COM/COMPLIANCE.